Evidence map›Paper›PMID 20188202›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2010

Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.

David A Rizzieri, Robert Storms, Dong-Feng Chen, Gwynn Long, Yiping Yang, Daniel A Nikcevich, Cristina Gasparetto, Mitchell Horwitz, John Chute, Keith Sullivan and 8 more

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00586690 phase1completednot on this map

Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions(DLI) From 6/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)

TypeinterventionalSponsorDavid Rizzieri, MDRan2005 to 2013Enrolled47ConditionsLymphomaArmsNK Cell infusion using CD56 monoclonal antibody, Donor Apheresis
NCT00586703 phase1completednot on this map

Safety Trial of Natural Killer (NK) Cell Donor Lymphocyte Infusions (DLI) From 3-5/6 Human Leukocyte Antigen (HLA) Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation (ASCT)

TypeinterventionalSponsorDavid Rizzieri, MDRan2005 to 2013Enrolled21ConditionsLymphomaArmsNK-CD56
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 85 citations in OpenAlex.

  1. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

David A RizzieriDuke University Medical Center, Department of Medicine, Division of Cellular Therapy, Durham, North Carloina, 27705, USA. rizzi003@mc.duke.edu
Robert Storms
Dong-Feng Chen
Gwynn Long
Yiping Yang
Daniel A Nikcevich
Cristina Gasparetto
Mitchell Horwitz
John Chute
Keith Sullivan
Therese Hennig
Debashish Misra
Christine Apple
Megan Baker
Ashley Morris
Patrick G Green
Vic Hasselblad
Nelson J Chao
Duke University Hospital · USDuke Medical Center · USDuke University · USDuluth Clinic · US

Funding

THERAPEUTIC APPROACHES TO OVARIAN/BREAST CANCER--HIGH DOSE CHEMOTHERAPY AND ABMSP01CA047741 · NCI · DUKE UNIVERSITY · PI YANG, YIPING · 1990 to 2013
$19.5M
Mentored Patient-Oriented Research Career Development AwK23RR016063 · NCRR · DUKE UNIVERSITY · PI RIZZIERI, DAVID A · 2000 to 2004
$626k
NCI NIH HHS 2P01-CA047741-15NCI NIH HHS P01 CA047741NCRR NIH HHS K23 RR016063
6 · The paper itself

Abstract

Infusing natural killer (NK) cells following transplantation may allow less infections and relapse with little risk of acute graft-versus-host disease (aGVHD). We delivered 51 total NK cell-enriched donor lymphocyte infusions (DLIs) to 30 patients following a 3-6/6 HLA matched T cell-depleted nonmyeloablative allogeneic transplant. The primary endpoint of this study was feasibility and safety. Eight weeks following transplantation, donor NK cell-enriched DLIs were processed using a CD56(+) selecting column with up to 3 fresh infusions allowed. Toxicity, relapse, and survival were monitored. T cell phenotype, NK cell functional recovery, and KIR typing were assessed for association with outcomes. Fourteen matched and 16 mismatched transplanted patients received a total of 51 NK cell-enriched DLIs. Selection resulted in 96% (standard deviation [SD] 8%) purity and 83% (SD 21%) yield in the matched setting and 97% (SD 3%) purity and 77% (SD 24%) yield in the mismatched setting. The median number of CD3(-) CD56(+) NK cells infused was 10.6 (SD 7.91) x 10(6) cells/kg and 9.21 (SD 5.6) x 10(6) cells/kg, respectively. The median number of contaminating CD3(+)CD56(-) T cells infused was .53 (1.1) x 10(6) and .27 (.78) x 10(6) in the matched and mismatched setting, respectively. Only 1 patient each in the matched (n = 14) or mismatched (n = 16) setting experienced severe aGVHD with little other toxicity attributable to the infusions. Long-term responders with multiple NK cell-enriched infusions and improved T cell phenotypic recovery had improved duration of responses (p = .0045) and overall survival (OS) (P = .0058). A 1-step, high-yield process is feasible, and results in high doses of NK cells infused with little toxicity. NK cell-enriched DLIs result in improved immune recovery and outcomes for some. Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery.

Indexed as

AdultHematopoietic Stem Cell TransplantationHLA AntigensHumansKiller Cells, NaturalLymphocytesLymphocyte TransfusionStem Cell TransplantationTissue DonorsTransplantation ConditioningTransplantation, HomologousHLA Antigens

Identifiers

PMID20188202
PMCPMC3625653
OpenAlexW2020709481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.